anti-inflammatory drug

Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea

Tokyo, October 01, 2020: Eisai Co., Ltd. and Seikagaku Corporation announced today that the companies have entered into an agreement…

4 years ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420